Mergers & Acquisitions ·
Neurocrine Biosciences filed an amendment to its Form 8-K to include audited financial statements for acquired entity…
NBIXNeurocrine Biosciences Inc
Neurocrine Biosciences filed an amendment to its Form 8-K to include audited financial statements for acquired entity Soleno Therapeutics and unaudited pro forma combined income statements. The filing confirms the completion of the acquisition on May 18, 2026, at a cash price of $53.00 per share. Neurocrine also entered into a five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank to fund working capital needs post-acquisition. The company drew and subsequently repaid $600 million under this facility by June 30, 2026. Pro forma results indicate combined revenues of $1.9 billion for the six months ended June 30, 2026, and $3.1 billion for the year ended December 31, 2025. Neurocrine Biosciences operates in the biotechnology industry, developing and commercializing innovative medicines for central nervous system disorders.